Integrated healthcare company, based in Singapore, Clearbridge Health Limited, through its subsidiary SAM Laboratory Pte Ltd, has completed the second phase of transactions related to the acquisition of controlling stake in PT Indo Genesis Medika (IGM Labs). In addition, SAM has completed the subscription of Rp22 billion for redeemable exchangeable bond that can be exchangeable to a 20% interest in IGM Labs.
